… Germany)) are all authorized in Europe as valid alternatives for vitamin K antagonists (VKA)
in patients with non-valvular … from clinical practice on both the effectiveness and the safety of …

… there is no RCT comparing efficacy and safety of DOACs and … that ld-DOAC therapy,
as practiced in Germany today, might … efficacy, and safety of Apixaban in patients with non-Valvular …

… and safely in clinical practice. Many unresolved questions on how to optimally use these drugs
in … , but the relative benefit of apixaban over warfarin was preserved, both for efficacy and …

… and have been introduced into clinical practice. In this review, … to treat the patient with
apixaban or rivaroxaban, treatment … , acenocoumarol (not approved in Germany) and warfarin. In …

… In clinical practice, this decision will often depend on a … However, the relative efficacy and
safety of factor Xa inhibitors … (Praxbind, Boehringer-Ingelheim, Germany) at a dose of 5 g for …

… (VKAs) or the non-vitamin K antagonist oral anticoagulants (… 4 and the factor Xa inhibitors
apixaban 5 , edoxaban 6 , and … these patients represent a milestone for the clinical practice. …

… vitamin K antagonist oral anticoagulants (NOACs) has profoundly changed anticoagulation
management for patients … net clinical benefit compared with vitamin K antagonists (VKAs) [2]. …

… among different NOACs in US clinical practice using single … showed consistent comparative
effectiveness and safety results … Vitamin K antagonists in heart disease: current status and …

… in atrial fibrillation (ARISTOTLE) trial, apixaban is comparable to a vitamin K antagonist (VKA…
of all NVAF patients treated with apixaban in routine German practice received the reduced …

… of current Polish AF patients and cardiologist practices, which will provide … efficacy, and
safety of Apixaban in patients with non-valvular atrial fibrillation in unselected patients in Germany…